Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiaf569 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von S J Hume und 22 weiteren Autor:innen. Beteiligte Einrichtung: St Vincent's Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B Surface Antigens, Antiviral Agents, Antigen-Antibody Complex. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council of Australia.
Abstract (Originalsprache)
Background and Aims Humoral immunity is thought to play a key role in the immunopathogenesis of chronic hepatitis B (CHB). Peaks in anti-HBs immune complexes (HBsAg-ICs) have been associated with subsequent HBsAg seroclearance. Discontinuation of nucleos(t)ide analog (NA) therapy can promote HBsAg seroclearance but also carries a risk of hepatitis flare. We evaluated the relationship between serum HBsAg-IC levels and hepatitis flare following NA cessation in HBeAg-negative CHB.
Methods
In a multicentre prospective cohort of noncirrhotic HBeAg-negative CHB patients undergoing NA discontinuation, we conducted a nested case-control analysis (n = 38). Stored serum samples were tested for HBsAg-IC at end-of-treatment (EOT) and at serial timepoints off-treatment. Cases (n = 24) experienced a hepatitis flare (ALT >5× upper limit of normal); controls (n = 14) did not. Associations between HBsAg-IC levels and clinical outcomes were analyzed.
Results
Serum HBsAg-ICs were detectable in 97% of participants at EOT. High HBsAg-IC levels (≥40 IU/mL) at EOT were less frequent among those who developed hepatitis flare (8%) versus controls (57%, P = .002). Individuals treated with tenofovir (vs other NAs) had lower EOT HBsAg-IC levels. Longitudinal analysis revealed dynamic increases in HBsAg-IC levels during hepatitis flare, peaking with maximal ALT. Participants who experienced beneficial flares (≥1 log₁₀ HBsAg reduction) had higher peak off-treatment HBsAg-IC levels compared to those with nonbeneficial flares.
Conclusions
Serum HBsAg-ICs are detectable in patients with CHB, and low levels at EOT are associated with the risk of hepatitis flare after NA cessation. These findings support the role of humoral immunity in CHB immunopathogenesis. Clinical Trials Registration The study clinical trial ID is NCT02581033.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- St Vincent's Hospital, Melbourne, Victoria, Australia.
- Department of Medicine, The University of Melbourne, Victoria, Australia.
- Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
- Western Health, Melbourne, Victoria, Australia.
- Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.
- Liverpool Hospital, Sydney, New South Wales, Australia.
ORCID-Profile: S J Hume, K Visvanathan, S Vogrin, S A L Hall, R Sawhney, S I Strasser, D Wong, M Littlejohn, N Warner
Förderung
- National Health and Medical Research Council of Australia
Zitieren
APA
Hume, S. J., Visvanathan, K., Cheng, K., Jackson, K., Vogrin, S., Hall, S. A. L., Burns, G. S., Desmond, P. V., Ratnam, D., Levy, M. T., Sawhney, R., Strasser, S. I., Ngu, M. C., Sinclair, M., Meredith, C., Matthews, G., Valaydon, Z., Wong, D., Littlejohn, M., …, & Warner, N. (2026). Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf569
Vancouver
Hume SJ, Visvanathan K, Cheng K, Jackson K, Vogrin S, Hall SAL, et al. Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiaf569
BibTeX
@article{Hume2026,
author = {Hume, S J and Visvanathan, K and Cheng, K and Jackson, K and Vogrin, S and Hall, S A L and Burns, G S and Desmond, P V and Ratnam, D and Levy, M T and Sawhney, R and Strasser, S I and Ngu, M C and Sinclair, M and Meredith, C and Matthews, G and Valaydon, Z and Wong, D and Littlejohn, M and Holmes, J A and Revill, P A and Thompson, A J and Warner, N},
title = {Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiaf569}
}
EUVIMED